Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares,…
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday’s regular session. The company’s market cap…
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis L…
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for
Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Edition Of Discovery On Target Meeting, In Boston, September 25-28, 2023
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry's
Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 97.3% to $1.6 during Tuesday’s regular session. Trading volume for this…
Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
